Astrazeneca plc — RNS

Regulatory news across AZN

Date	Time	Date	TitleTitle (filtered)	Source
14/11/22	07:05:05	14 Nov 2022	Imfinzi recommended for approval in the EU for BTC	Imfinzi recommended for approval in the EU for BTC	RNS
14/11/22	07:00:06	14 Nov 2022	Lynparza combo recommended in the EU for mCRPC	Lynparza combo recommended in the EU for mCRPC	RNS
11/11/22	07:00:06	11 Nov 2022	Imfinzi + Imjudo approved in US for lung cancer	Imfinzi + Imjudo approved in US for lung cancer	RNS
10/11/22	07:00:06	10 Nov 2022	YTD and Q3 2022 Results	YTD and Q3 2022 Results	RNS
09/11/22	07:00:08	9 Nov 2022	FDA Advisory Committee recommends PT027 in asthma	FDA Advisory Committee recommends PT027 in asthma	RNS
04/11/22	07:00:03	4 Nov 2022	Beyfortus (nirsevimab) approved in EU	Beyfortus (nirsevimab) approved in EU	RNS
01/11/22	15:00:02	1 Nov 2022	Total Voting Rights	Total Voting Rights	RNS
26/10/22	07:00:05	26 Oct 2022	Capivasertib Phase III trial met primary endpoints	Capivasertib Phase III trial met primary endpoints	RNS
25/10/22	07:00:06	25 Oct 2022	Update on MESSINA Phase III trial	Update on MESSINA Phase III trial	RNS
24/10/22	07:00:09	24 Oct 2022	Imfinzi + Imjudo approved in advanced liver cancer	Imfinzi + Imjudo approved in advanced liver cancer	RNS
03/10/22	15:00:01	3 Oct 2022	Total Voting Rights	Total Voting Rights	RNS
30/09/22	10:30:07	30 Sept 2022	Board Committee Changes	Board Committee Changes	RNS
27/09/22	07:05:05	27 Sept 2022	Koselugo approved in Japan for NF1	Koselugo approved in Japan for NF1	RNS
27/09/22	07:00:07	27 Sept 2022	Tezspire approved in Japan for severe asthma	Tezspire approved in Japan for severe asthma	RNS
23/09/22	07:00:08	23 Sept 2022	Ultomiris approved in EU for gMG	Ultomiris approved in EU for gMG	RNS
22/09/22	07:00:14	22 Sept 2022	Lynparza approved in China for ovarian cancer	Lynparza approved in China for ovarian cancer	RNS
21/09/22	07:00:06	21 Sept 2022	Tezspire approved in the EU for severe asthma	Tezspire approved in the EU for severe asthma	RNS
20/09/22	07:00:13	20 Sept 2022	Evusheld approved in EU for COVID-19 treatment	Evusheld approved in EU for COVID-19 treatment	RNS
16/09/22	07:10:01	16 Sept 2022	Danicopan Phase III trial met primary endpoint	Danicopan Phase III trial met primary endpoint	RNS
16/09/22	07:05:00	16 Sept 2022	Evusheld positive CHMP opinion in EU	Evusheld positive CHMP opinion in EU	RNS
16/09/22	07:00:04	16 Sept 2022	Nirsevimab recommended for approval in EU by CHMP	Nirsevimab recommended for approval in EU by CHMP	RNS
05/09/22	07:05:05	5 Sept 2022	Forxiga approved in China for CKD	Forxiga approved in China for CKD	RNS
05/09/22	07:00:07	5 Sept 2022	Imfinzi approved in US for biliary tract cancer	Imfinzi approved in US for biliary tract cancer	RNS
01/09/22	15:00:04	1 Sept 2022	Total Voting Rights	Total Voting Rights	RNS
30/08/22	13:00:01	30 Aug 2022	Evusheld approved for COVID-19 in Japan	Evusheld approved for COVID-19 in Japan	RNS
30/08/22	07:01:04	30 Aug 2022	Farxiga shows CV mortality benefit across EF range	Farxiga shows CV mortality benefit across EF range	RNS
30/08/22	07:00:13	30 Aug 2022	Farxiga reduced risk of CV death or worsening HF	Farxiga reduced risk of CV death or worsening HF	RNS
25/08/22	07:10:01	25 Aug 2022	Ultomiris approved in Japan for gMG	Ultomiris approved in Japan for gMG	RNS
25/08/22	07:05:00	25 Aug 2022	Tagrisso approved in Japan for early lung cancer	Tagrisso approved in Japan for early lung cancer	RNS
25/08/22	07:00:03	25 Aug 2022	Lynparza approved in Japan for early breast cancer	Lynparza approved in Japan for early breast cancer	RNS
16/08/22	07:00:11	16 Aug 2022	Lynparza granted FDA priority review for PROpel	Lynparza granted FDA priority review for PROpel	RNS
15/08/22	07:00:06	15 Aug 2022	Enhertu improved PFS in mBC in DESTINY-Breast02	Enhertu improved PFS in mBC in DESTINY-Breast02	RNS
12/08/22	07:00:09	12 Aug 2022	Enhertu approved in US for HER2-mutant NSCLC	Enhertu approved in US for HER2-mutant NSCLC	RNS
11/08/22	07:00:12	11 Aug 2022	Acquisition of TeneoTwo completed	Acquisition of TeneoTwo completed	RNS
08/08/22	07:10:05	8 Aug 2022	Enhertu approved in the US for HER2-low mBC	Enhertu approved in the US for HER2-low mBC	RNS
04/08/22	07:00:07	4 Aug 2022	Lynparza approved in EU for early breast cancer	Lynparza approved in EU for early breast cancer	RNS
01/08/22	17:00:02	1 Aug 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/08/22	15:05:01	1 Aug 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/08/22	15:00:01	1 Aug 2022	Total Voting Rights	Total Voting Rights	RNS
29/07/22	07:01:05	29 Jul 2022	Chair succession	Chair succession	RNS
29/07/22	07:00:11	29 Jul 2022	Half-year Report	Half-year Report	RNS
25/07/22	07:10:05	25 Jul 2022	Tezspire recommended for EU approval in asthma	Tezspire recommended for EU approval in asthma	RNS
25/07/22	07:05:06	25 Jul 2022	Ultomiris recommended for EU approval for gMG	Ultomiris recommended for EU approval for gMG	RNS
25/07/22	07:00:06	25 Jul 2022	Enhertu granted Priority Review for HER2-low mBC	Enhertu granted Priority Review for HER2-low mBC	RNS
19/07/22	07:00:07	19 Jul 2022	Enhertu approved in EU for HER2-positive mBC	Enhertu approved in EU for HER2-positive mBC	RNS
05/07/22	07:00:04	5 Jul 2022	AstraZeneca to acquire TeneoTwo and T cell engager	AstraZeneca to acquire TeneoTwo and T cell engager	RNS
01/07/22	15:00:12	1 Jul 2022	Total Voting Rights	Total Voting Rights	RNS
30/06/22	07:00:08	30 Jun 2022	Imfinzi improved pCR in resectable lung cancer	Imfinzi improved pCR in resectable lung cancer	RNS
27/06/22	07:05:04	27 Jun 2022	Enhertu recommended for breast cancer EU approval	Enhertu recommended for breast cancer EU approval	RNS
27/06/22	07:00:08	27 Jun 2022	Lynparza recommended in EU for early breast cancer	Lynparza recommended in EU for early breast cancer	RNS

Showing 351–400 of 485 announcements